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OBJECTIVE: The objective of this study was to determine the proportion of patients with atherosclerotic
peripheral vascular disease (PVD) who had elevated lipoprotein(a) [Lp(a)] levels, as well as to determine
the latter’s significance as a risk factor for PVD in the local population.
METHODS: This case-controlled study was conducted between June and October 2004 in the Department
of Surgery, Kuala Lumpur Hospital. A total of 100 patients were recruited and divided into control and
PVD groups. Patients were defined as having PVD if they were symptomatic, with ankle-brachial systolic
index < 0.90, or by radiological evidence. Lp(a) concentrations were determined using immunoturbidometry.
Absorbance of reaction precipitate was measured by spectrophotometry to give Lp(a) concentration in
grams per litre (g/L). The reference value for normal Lp(a) levels was ≤ 0.36 g/L.
RESULTS: Mean Lp(a) levels for control and PVD groups were 0.29 g/L and 0.56 g/L, and median values
were 0.17 g/L and 0.48 g/L, respectively. Elevated Lp(a) levels in the control group was 26% compared to
58% in the PVD group. Analysis with Pearson’s χ2 test achieved a significant p value of 0.001. Multivariate
analysis showed that elevated Lp(a) levels contributed significantly to the probability of having PVD with
an odds ratio of 7.69.
CONCLUSION: Elevated serum Lp(a) has a significant role as a risk factor for atherosclerotic PVD in
the local population. [Asian J Surg 2008;31(1):11–5]
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Introduction
Lipoprotein (Lp)(a) has been shown to be an indepen-
dent risk factor for atherosclerosis.1–5 Early studies found
a strong relationship between Lp(a) and coronary heart
disease (CHD) through epidemiological observations.
These epidemiological studies suggested a link between
elevated Lp(a) levels and accelerated atherosclerosis.
Subsequent animal and in vivo studies revealed evidence
supporting these observations.6–9
Peripheral vascular disease (PVD), CHD and cerebrovas-
cular disease are all part of the same disease spectrum of
atherosclerosis. Based on the earlier observations of elevated
Lp(a) and CHD, studies were performed to see if the same
could be inferred with regard to atherosclerotic PVD.
Several reports have been published, confirming elevated
Lp(a) level to be an independent risk factor for atheroscle-
rotic PVD as well.10–13
Levels of Lp(a) more than 0.30 g/L has been quoted in
many studies as the cut-off value that separates individuals
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with normal levels from those with elevated concentra-
tions.1 Subjects with Lp(a) concentrations above this value
have significant risk of accelerated atherosclerotic PVD.
The aim of this study was to determine the proportion
of patients with atherosclerotic PVD who had elevated
serum Lp(a), as well as the latter’s significance as a risk
factor for PVD in our local hospital population.
Patients and methods
This was a prospective case-controlled study conducted
from 1 June 2004 to 30 October 2004 in the Department
of General Surgery, Hospital Kuala Lumpur. Patients
between the ages of 40 and 80 years were recruited and
divided into control and PVD groups.
Inclusion criteria for the PVD group were those symp-
tomatic of PVD, with intermittent claudication, rest pain
or non-healing ulcer, with ankle-brachial systolic index
(ABSI) < 0.90,14 or with radiological evidence of athero-
sclerotic PVD (by magnetic resonance angiogram/digital
subtraction angiogram of the lower limbs).
The control group consisted of patients with non-
related surgical problems recruited from the general sur-
gical clinic or wards. These patients were selected to
match for age and sex to those in the PVD group. All con-
trol subjects were examined to exclude asymptomatic PVD.
Patients diagnosed with malignancy, chronic liver disease,
thrombotic tendencies and renal failure were excluded
from the study.
Parameters recorded were age, sex, weight, height,
smoking habits, past medical history of diabetes mellitus,
hypertension, coronary artery disease and hyperlipidaemia.
Peripheral pulses were palpated and recorded using 
a hand-held Doppler machine (IMEXDOP CT+ with
a T800 8-MHz vascular probe; Nicolet Vascular, VIASYS
Healthcare Inc.). ABSI measurements were done using the
same Doppler machine.
Blood samples were collected by venepuncture after
overnight fast. Biochemical risk factors determined 
included fasting blood glucose, serum creatinine, total
cholesterol, triglycerides and lipid fractions. Haematolog-
ical parameters were measured using standard laboratory
methods, and these included haemoglobin, white blood
cell and platelet counts, prothrombin time and activated
partial thromboplastin time. These parameters were 
used to screen subjects for undiagnosed concurrent ill-
nesses, namely diabetes mellitus and hyperlipidaemia;
and to exclude those with renal failure and thrombotic
tendencies.
Serum Lp(a) level was determined by particle-enhanced
immunoturbidometric assay. Blood was collected in a spec-
imen bottle containing ethylenediamine tetraacetic acid,
which was then sent to the laboratory and separated by
centrifugation at 4,000 rpm for 5 minutes. Collected serum
samples were transferred into plain specimen containers
and kept frozen at −70°C until the time of analysis. Prior
to analysis, the frozen specimens were allowed to thaw
gradually to room temperature. Lp(a) assay was performed
using COBAS INTEGRA 800 (Roche Diagnostics, Basel,
Switzerland) with Tina-quant® Lipoprotein(a) (Latex)
reagents. The basis of this test is that human Lp(a) agglu-
tinates with latex particles coated with anti-Lp(a) anti-
bodies, forming a turbid solution. The turbidity of the
precipitate is determined using a spectrophotometer. The
reading is then taken at a wavelength of 552 nm. The system
has a lower detection limit of 0.08 g/L.
Statistical analysis
Statistical analyses were performed using SPSS version
10.0 (SPSS Inc., Chicago, IL, USA). The incidence of ele-
vated serum Lp(a) was calculated accordingly for each
group. Pearson’s χ2 and Mann-Whitney U tests were used
to calculate statistical significance. Multivariate analysis
using logistic regression was performed to assess the sig-
nificance of these variables as risk factors for PVD, expressed
in odds ratio values. A p value less than 0.05 was used to
indicate statistical significance.
Results
Demographic data
A total of 100 patients were recruited. Each group had 50
subjects. Table 1 shows the basic demographic data of the
study population. The racial distribution in the study
groups consisted of 40% Malays, 35% Chinese and 25%
Indians. The proportions of each ethnic group were 
balanced in both control and PVD groups.
Lp(a) analysis
The distribution of Lp(a) levels in the whole study popu-
lation was skewed to the right with a large proportion of
patients at the lower end of the spectrum. More than 50%
of patients had a Lp(a) level < 0.29 g/L. The mean Lp(a)
level of the whole study population was 0.43 g/L (Figure 1).
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Analysis of Lp(a) levels in the two groups revealed a sig-
nificant difference. Serum Lp(a) concentration in the con-
trol group ranged from 0.08 to 0.88 g/L, with a mean of
0.29 g/L (95% confidence interval [CI], 0.22–0.35 g/L) and
a median of 0.17 g/L. In the PVD group, Lp(a) levels ranged
from 0.08 to 1.51 g/L, with a mean of 0.56 g/L (95% CI,
0.45–0.68 g/L) and a median of 0.48 g/L (Figure 2).
The proportion of patients with elevated Lp(a) levels
in the control group was 26%, whereas it was 58% in the
PVD group. Analysis using Pearson’s χ2 test achieved 
statistical significance with a p value of 0.001 (Table 2).
Analysis using the Mann-Whitney U test, taking into
account the skewed serum Lp(a) distribution in the study
population, showed a significant difference in serum Lp(a)
levels between the control and PVD groups (p = 0.001).
Elevated Lp(a) levels among ethnic groups
Elevated Lp(a) levels were seen in 40% of Malays, 38% of
Chinese and 52% of Indians. Analysis of these figures did
not show any statistically significant difference.
Risk factor analysis
Analysis of common risk factors of atherosclerosis
showed that there was a significantly higher prevalence of
patients with ischaemic heart disease, diabetes mellitus
and smoking in the PVD group compared to the control
group. Obesity, hypertension and hyperlipidaemia were
not significantly different between the two groups 
(Table 3).
Further multivariate analysis using linear regression
showed that four factors contributed significantly to the
likelihood of developing atherosclerotic PVD in the study
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Table 1. Demographic data of the study population
Control, n (%) PVD, n (%)
Gender
Male 43 (86) 43 (86)
Female 7 (14) 7 (14)
Age, yr
Mean 64.5 64.1
Range 42–78 41–78
Racial distribution
Malay 22 (44) 18 (36)
Chinese 16 (32) 19 (38)
Indian 12 (24) 13 (26)
PVD = peripheral vascular disease.
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Figure 1. Distribution of lipoprotein(a) levels in the whole study
population. SD = standard deviation.
Table 2. Prevalence of elevated lipoprotein (Lp)(a) levels*
Control, n (%) PVD, n (%) Total, n
Lp(a) level, g/L
Normal (≤ 0.36) 37 (74) 21 (42) 58
Elevated (> 0.36) 13 (26) 29 (58) 42
Total 50 50 100
*Pearson’s χ2 test, p = 0.001. PVD = peripheral vascular disease.
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Figure 2. Distribution of lipoprotein(a) levels by group. PVD =
peripheral vascular disease.
population. In order of significance, they were smoking
habit, elevated serum Lp(a), diabetes mellitus and ischaemic
heart disease (Table 4).
Discussion
Elevated Lp(a) level has been established as an independent
risk factor for atherosclerotic diseases.1–5,10–13 This is clin-
ically translated into accelerated development of coronary
artery disease, cerebrovascular disease and PVD. This
study explored the relationship between Lp(a) and athero-
sclerotic PVD in the local hospital population.
The overall frequency distribution of Lp(a) levels in
this study showed a curve that was highly skewed to the
right. More than 50% of the patients had Lp(a) levels less
than the cut-off value of 0.36 g/L. This is comparable to
the results of previously reported studies. In general, the
Lp(a) levels of a large proportion of a particular popula-
tion will be at the lower end of the spectrum.6,15
The prevalence of elevated Lp(a) level was previously
quoted to be approximately 20%. In our study, 26% of
those in the control group had raised Lp(a) levels. This
figure is slightly higher than the reported figure, but not
significantly different. Among patients in the PVD group,
56% had elevated Lp(a) levels. This is almost double that
of the control group, and approximately triple the figure
in the Framingham Offspring Study.16 Univariate analysis
of these values showed statistical significance (p < 0.001).
After controlling for other confounding variables,
logistic regression analysis showed that smoking, elevated
serum Lp(a), diabetes mellitus and ischaemic heart 
disease contributed significantly to the probability of hav-
ing atherosclerotic PVD, with odds ratios of 18.37, 7.69,
7.50 and 3.61, respectively. In effect, based on this popu-
lation sample, having elevated serum Lp(a) predisposes a
person to more than 7 times the risk of developing athero-
sclerotic PVD compared to a person with normal Lp(a)
levels.
Factors reported to affect Lp(a) level include liver dis-
ease, renal failure, inherent defects in lipid metabolism,
and diabetes.15,17–20 In this study, patients with liver dis-
ease and renal failure were excluded by screening of renal
and liver functions. Those on lipid lowering medication
were not excluded as the evidence on the effect of antilipid
drugs remains inconclusive. The main effects of lipid low-
ering medications are on altering Lp(a)/oxidized phos-
pholipid complex formation, and not directly on Lp(a)
levels.16,21,22
The reference value for elevated serum level has
remained an issue in Lp(a) assays. Many factors contribute
to this problem. Firstly, Lp(a) levels vary greatly between
populations and individuals. Secondly, there are various
methods of Lp(a) assays, leading to a lack of standardiza-
tion. The introduction of automated immunoturbido-
metric assays has improved the situation significantly.
This method is deemed accurate and almost as good 
as performing an ELISA analysis. This is the method that
was used in this study. The reference value for Lp(a) used
in this study was obtained from a recently concluded
unpublished local study of blood donors at the National
Blood Bank. Serum Lp(a) levels > 0.36 g/L were consid-
ered to be elevated. This value is the adopted standard for
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Table 3. Analysis of the prevalence of risk factors for peripheral vascular disease (PVD)
Risk factor Control, n (%) PVD, n (%) p
Overweight 13 (26) 11 (22) 0.64
Hypertension 22 (44) 28 (56) 0.54
Ischaemic heart disease 6 (12) 23 (46) < 0.05*
Diabetes 11 (22) 31 (62) < 0.05*
Hyperlipidaemia 10 (20) 16 (32) 0.17
Smoking 16 (32) 41 (82) < 0.05*
*Statistical significance.
Table 4. Logistic regression analysis for risk factors for peripheral
vascular disease
Factor OR (95% CI) p
Smoking 18.37 (4.68–72.09) < 0.001
Elevated serum Lp(a) 7.69 (2.11–28.02) 0.002
Diabetes mellitus 7.50 (2.29–24.51) 0.001
Ischaemic heart disease 3.61 (1.05–12.40) 0.041
OR = odds ratio; CI = confidence interval; Lp(a) = lipoprotein(a).
Lp(a) assays using the immunoturbidometry method in
the Chemical Pathology laboratory of Hospital Kuala
Lumpur. It is a fraction higher than the accepted world-
wide reference value of 0.30 g/L,15 but it was deemed to 
be more reflective of the multiracial nature of the local
population.
The multiracial background of the local population
presents an interesting point of discussion. Most reported
studies are with data based on Caucasian populations.
There have been some reports based on Chinese popula-
tions10 but none on Malays or Indians, the other two main
ethnic groups comprising the local population. Analysis
of this study’s results showed that among the three racial
groups, Indians had the highest proportion of elevated
Lp(a) levels. The Malays and Chinese also had significant
proportions of elevated Lp(a) levels, but statistical analysis
failed to show any significance, possibly due to the small
sample size.
In summary, this small pilot study has shown that 
elevated serum Lp(a) correlates with atherosclerotic PVD
in the local population. This study also confirmed that in
the local population, Lp(a) plays a role as an independent
risk factor for atherosclerotic PVD.
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